Plasma Proteins Create Alzheimer's Risk Clock That Outperforms Standard Biomarkers

Alzheimer's disease progression involves complex molecular changes that current biomarkers may not fully capture. While plasma biomarkers like amyloid and tau proteins are less invasive than brain scans, they still miss important biological processes underlying disease development.

Researchers at Indiana University analyzed plasma samples from 498 participants using the SomaScan platform to measure nearly 7,000 proteins. They created organ-specific aging clocks and used pseudotime analysis to map disease progression as a continuous molecular trajectory rather than discrete diagnostic categories.

The cognition-optimized brain aging clock and liver aging acceleration showed significant associations with Alzheimer's diagnosis and established biomarkers including amyloid PET scans and plasma tau levels. The pseudotime analysis revealed a molecular trajectory from cognitively normal individuals to those with Alzheimer's, correlating with both plasma and imaging biomarkers.

Most importantly, these protein-based signatures improved diagnostic performance when added to existing biomarker panels. The pseudotime analysis alone outperformed established plasma biomarkers for distinguishing between diagnostic groups, suggesting it captures disease-relevant biological processes not detected by current methods.

These findings could lead to more accurate, accessible blood tests for Alzheimer's risk assessment and disease monitoring. The approach provides insights into biological aging processes and disease mechanisms that may inform therapeutic development and early intervention strategies.